Decoding the business of brain–computer interfaces

Fifty years after the term brain–computer interface was coined, the neurotechnology is being pursued by an array of start-up companies using a variety of different technologies. But the path to clinical and commercial success remains uncertain.
Of the companies developing BCIs (brain-computer interface) with implanted recording systems, two are exclusively pursuing ECoG (electrocorticography) devices.
The year 2023 promises to be significant for BCIs. Multiple non-invasive systems are likely to enter the hands of researchers and clinicians, and several key clinical trials of implanted systems are scheduled to begin. To succeed, BCIs must establish themselves as safe and truly helpful to people with serious medical conditions.
Author(s) Source
Drew L Nature Electronics volume 6pages90–95 (2023)
This is a post of a scientific or business information. The information given here is checked thoroughly by “Implant-Register”. However we can´t be responsible for the content. The content usually is shortened to make it understandable for many. Read the linked original text if you are interested. Contact the publisher, if you have questions. You may inform us about changes of the information to improve the Register.
Comments: n/a
let us know